• Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.

  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
日本語

個々のお客様向け組織モデル＆アッセイ法開発

特定のお客様向けヒト組織および病態モデル開発

新たな表現型組織培養モデルを開発し、ターゲットディスカバリー、リード最適化及び毒性の探索評価をサポートします。我々のモデル開発の専門性とお客様のノウハウを組み合わせ、お客様が直面する問題に対する答えを見つけていきましょう。ヒト生理機能や薬物の効果に対する新たなひらめきに繋がるかも知れません

ご期待に応えるべく
我々が最優先に考える事は、インパクトのある実験デザインおよびコラボ期間中を通してのコミュニケーションです。プロジェクトチームを作りアッセイ法最適化を計画し、ひたむきに実行します。ミーティングを毎月行い、報告や議論をしながら研究を進めます。モデルおよびアッセイ開発及び技術移管も行います。お客様のご要望に応じて化合物スクリーニングおよびプロファイリングサービスも実施します。

コラボレーションの機会をお待ちしています！
高い水準でお客様との効果的な共同研究や長期にわたっての関係を培い、研究プログラムに目に見えるインパクトを与えます。我々はお客様の成功を最優先に考え、お客様の研究の明確な問題にフルに答えることができるよう綿密なプランを立てます。

MIMETASの注目分野をもっと知りたい方やブレインストーミングを希望される方は、コンタクトフォームまたはお電話にてお問い合わせ下さい。

お問合せ

ヒト組織および病態モデル作製の最新技術

Other services

化合物スクリーニングとプロファイリング
ヒト組織モデルで再現性あるデータを取得。確立されたOrganoPlate®によるフェノティピックなアッセイでお客様の創薬研究ニーズをサポートします。

創薬研究パートナーシップ
我々の研究チームと肩を組んで進めれば、あなたの創薬研究の世界が広がります。OrganoPlate®で独自のヒト病態モデル研究を共に進め、明日の治療薬を創りましょう


 


サービス概要

Get inspired

Case Study
Antibody Transcytosis across the Blood-Brain Barrier in collaboration with Biogen.

Case Study
Transendothelial Migration of Immune Cells towards a Tumor Microenvironment in collaboration with AstraZeneca.

Case Study
IBD Disease Model and Assays in collaboration with PMI.

Knowledge Center

革新はすぐそこに

What customers say
'
Our exciting collaboration enables our research and early development group to apply state-of-the-art organ-on-a-chip technology in the modeling of IBD and HBV. These models have the potential to improve our understanding of disease biology and transform
The 'I' in MIMETAS
'
Tackling challenges together.
What customers say
'
"The OrganoReady Colon Caco-2, combined with the OrganoTEER, have become our gold standard in vitro model for the screening of intestinal barrier disruptors at SIAF. "
What customers say
'
The OrganoPlate Caco-2 model is for us, at Merck, the most suitable platform offering at the same time scalability, speed, robustness, ease of handling, with low compound needs.
The 'I' in MIMETAS
Chiwan Chiang
Marketing Specialist
'
A day without
laughter is a day wasted.
Read more
What customers say
'
Mimetas' tumor infiltration platform demonstrated a therapeutic effect of our compound on immune cell recruitment: we’re very excited by these proof of concept data
The 'I' in MIMETAS
Jos Joore
CEO
'
We want to
empower research on complex tissue biology.
Read more
What customers say
'
Often you have to compromise it’s either the throughput or it’s the complexity of the model. Getting both in the same platform… no other platform can do that!
The 'I' in MIMETAS
Nienke Wevers
Senior Scientist
'
Nothing ventured, nothing gained.
Read more
What customers say
'
We were able to measure cell barrier permeabilities in a lung-on-a-chip model demonstrating superior sensitivity and translatability than any other lung cell model we tried before. It was also very easy to scale up our data generation workflow.
The 'I' in MIMETAS
Henriëtte Lanz
Director of Model Development
'
It should be
mandatory to
socialize with colleagues.
Read more
What customers say
'
Organoplates opened avenues that were before considered unreachable
The 'I' in MIMETAS
Bas Trietsch
Chief Technology Officer
'
We try to help
each other
as a team.
Read more
The 'I' in MIMETAS
Jacquelien Ten Dam
Chief Financial Officer
'
It always seems impossible until it’s done.
Read more
The 'I' in MIMETAS
Paul Vulto
CEO
'
Leveraging who you are, is the key to making a difference!
Read more
The 'I' in MIMETAS
Linda Gijzen
Scientific Project Lead
'
Tackling challenges together.
Read more
The 'I' in MIMETAS
Tina Thakkar
Associate Director of Sales
'
It is not really
work if you are
having fun.
Read more
The 'I' in MIMETAS
Liis Rannamäe
Laboratory Technician
'
Can be summarized in three words - engaging, playful, and innovative.
Read more
The 'I' in MIMETAS
Mieke Doornbos
Vice President Sales & Marketing
'
Celebrate
good times.
Read more
The 'I' in MIMETAS
Frederik Schavemaker
Product Design Engineer
'
Pioneering, bringing the best solutions
for scientific
discovery.
Read more
The 'I' in Mimetas
Remko van Vught
Vice President Business Development
'
Making
a difference
together.
Read more
The 'I' in MIMETAS
Lenie van den Broek
Director Biology Discovery
'
Dynamic and innovative - each day holds a surprise.
Read more
The 'I' in Mimetas
Arnaud Nicolas
Associate Director TechCore
'
Own your flaws.
Read more
Latest Whitepaper
'
Closing the Translational Gap in Cancer Drug Discovery with Comprehensive Tumor Models
Scientist
From a top pharma
New Webinar
'
Phenotypic Disease Modeling for Immuno-Oncology: Putting Targets into Patient Context

 

 



By MIMETAS and Molecular Devices
Register here

Press Release
'
MIMETAS and Astellas Enter into Strategic Partnership on Immuno-oncology
Scientist
From a top pharma
News Article
'
First Large-scale Phenotypic Screen Using Organ-on-a-Chip

 

 



By MIMETAS and Molecular Devices
Register here

Cookies

May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all